RIF1 and ovarian cancer: Because platinum-based chemotherapeutics utilize double-stranded breaks to cause cell death, overexpression of RIF1 in ovarian cancer would reverse any damage done by chemotherapeutics; therefore, its potential to be a therapeutic target is promising.